Dosing CJC 1295 DAC typically ranges from 1–2 mg once or twice weekly, but the long half-life changes timing, saturation, and side effects.
CJC-1295 DAC is a long-acting growth hormone-releasing hormone (GHRH) analog, and the most commonly cited research dose is 1 mg to 2 mg per week, given as a single injection or split into two. The DAC (Drug Affinity Complex) extends the peptide's half-life to roughly 6 to 8 days, so weekly dosing replaces the multiple daily injections used with shorter GHRH analogs.
CJC-1295 DAC is not FDA-approved for human use in the United States. Everything below describes laboratory protocols and published research, not a medical recommendation, and anyone weighing use should consult a licensed healthcare professional.
Why DAC Changes the Dosing Math
Native GHRH and the non-DAC peptide, often called Mod GRF 1-29, are cleared from the bloodstream within minutes. The DAC side chain binds the molecule to albumin, which acts as a circulating reservoir and releases the peptide slowly over days.
That single modification turns a pulsatile, short-acting compound into a sustained one. Many researchers also look into cjc-1295 dac vs no dac before committing to a schedule, because the two versions behave very differently once injected.
| Feature | CJC-1295 with DAC | CJC-1295 without DAC |
|---|---|---|
| Approximate half-life | 6–8 days | About 30 minutes |
| Typical injection frequency | Once or twice weekly | 2–3 times daily |
| Common research dose | 1–2 mg per week | 100 mcg per injection |
| Albumin binding | Yes | No |
| Growth hormone pattern | Sustained elevation | Pulse-like spikes |
Typical Dosing Ranges Reported in Research
Weekly totals cluster around 1 mg to 2 mg in most published work. Splitting the weekly amount into two smaller injections is common because it produces steadier blood levels and may soften peak-related side effects.
| Weekly total | Common split | Notes |
|---|---|---|
| 1 mg | Single injection | Lowest dose commonly cited in the literature |
| 1 mg | 500 mcg twice weekly | Smoother exposure across the week |
| 2 mg | Single injection | Upper end of the typical research range |
| 2 mg | 1 mg twice weekly | Most frequently described split |
A cjc-1295 with dac dosing protocol usually spreads the weekly total across one or two injections rather than escalating day by day. Dose escalation is uncommon because the compound already stays active for a full week and does not need to build up in the body.
Timing, Frequency, and the Saturation Question
Timing matters far less with DAC than with the short-acting version. Because blood levels remain elevated for days, the exact hour of injection has much less influence on the overall hormone profile.
Even so, many researchers still inject in the evening, when natural growth hormone release peaks during deep sleep. Others prefer a fixed weekly slot, such as the same evening every seven days, to keep the schedule simple and consistent.
The idea of a saturation dose describes the point at which higher amounts no longer increase growth hormone output and only add side effects. Research reports suggest that point arrives well below the largest doses some users discuss online.
For comparison, cjc-1295 no dac dosing is measured in micrograms and repeated two or three times a day, often timed just before a natural GH pulse. The two compounds are not interchangeable on a milligram-for-microgram basis.
Side Effects and Safety Considerations
Reported side effects in small human studies include redness or irritation at the injection site, flushing, headache, fatigue, and transient water retention. Most were mild and resolved without treatment.
Longer-term concerns center on sustained elevations in growth hormone and IGF-1. Persistently high IGF-1 is associated with insulin resistance and other metabolic issues, which is one reason long-acting GHRH analogs are handled cautiously in clinical research.
- Injection-site reactions such as redness, swelling, or mild pain
- Flushing, warmth, or a temporary headache shortly after dosing
- Fluid retention, joint stiffness, or tingling in the hands
- Elevated IGF-1 with prolonged use
Long-acting GHRH analogs produce sustained hormone elevation rather than the natural pulses seen with short-acting peptides, and that difference is central to any safety discussion.
People with existing hormone-sensitive conditions, diabetes, or a personal history of cancer should be especially cautious. A physician who understands peptide research can review individual risks and interactions.
Storage, Purity, and Buying Considerations
Lyophilized CJC-1295 DAC is typically stored refrigerated or frozen and protected from light. Once reconstituted with bacteriostatic water, it is usually kept refrigerated and used within a few weeks.
Vials arrive in several sizes, and researchers often compare cjc-1295 dac 10mg and smaller formats when calculating how long a single vial will last. Any listing that offers cjc 1295 dac for sale should provide a current third-party certificate of analysis showing purity above 98% by HPLC.
Red flags include missing COAs, unusually low prices, unclear labeling, and vendors who make medical claims. Because the compound is sold for research purposes only, no legitimate supplier should advertise it as a treatment for any condition.
The Bottom Line on Dosing CJC-1295 DAC
The most common research dose of CJC-1295 DAC is 1 mg to 2 mg per week, injected once or split into two doses. The 6-to-8-day half-life, not daily timing, drives the schedule.
CJC-1295 DAC is not approved by the FDA for human use, and dose information drawn from research settings should never replace guidance from a qualified healthcare provider.
Frequently Asked Questions
What is the typical dose of CJC-1295 DAC?
Published research protocols most often use 1 mg to 2 mg per week, given as a single injection or divided into two doses. The 6-to-8-day half-life is the reason weekly dosing is common. CJC-1295 DAC is not FDA-approved for human use in the United States.
How often should CJC-1295 DAC be injected?
Once or twice weekly in most research protocols. Albumin binding keeps the peptide active for roughly 6 to 8 days, so daily injections are not required with the DAC version. The non-DAC version must be injected two or three times daily because its half-life is only about 30 minutes.
Is CJC-1295 DAC legal to buy in the United States?
It is sold as a research chemical rather than an approved drug. The FDA has not approved CJC-1295 DAC for human use, so legitimate vendors label it for laboratory research only. Buyers should confirm that a current third-party certificate of analysis is available before purchasing.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.